Urinary bladder cancer is a common malignancy, being characterized by substantial patient
mortality and management cost. Its high somatic-mutation frequency and molecular …

Histone deacetylases (HDACs) influence diverse cellular processes and may contribute to
tumor development and progression by multiple mechanisms. Class I HDACs are often …

Class I histone deacetylases HDAC1 and HDAC2 contribute to cell proliferation and are
commonly upregulated in urothelial carcinoma. To evaluate whether specific inhibition of …

Epigenetic aberrations are prominent in bladder cancer (BC) and contribute to disease
pathogenesis. We characterized histone deacetylase (HDAC) expression, a family of …

Abstract Background Histone deacetylase inhibitors (HDACi) are promising anti-cancer
drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear …

What's known on the subject? and What does the study add? A growing body of evidence
supports the anti-cancer effect of histone deacetylase inhibitors (HDACi) in vitro, via multiple …

Abstract Background Histone deacetylases (HDACs) are known to be associated with an
overexpression in different types of cancer such as colon and prostate cancer. In this study …

Histone deacetylases (HDACs) are enzymes that remove acetyl groups from histones and
have attracted attention as potential targets for cancer therapy. Several small molecule …

Background Previous studies have shown that class-I histone deacetylase (HDAC) 8 mRNA
is upregulated in urothelial cancer tissues and urothelial cancer cell lines compared to …

OBJECTIVE To examine the expression profile of histone deacetylase (HDAC)‐1 and
explore its potential role in the development of bladder cancer, using valproic acid (VPA), a …